Strategic Partnerships TFF plans to expand via collaborations with large pharmaceutical partners, and has demonstrated momentum with partnerships involving Emory University and BARDA. Target opportunities include respiratory and infectious disease programs that could benefit from improved inhalable delivery and manufacturing scalability.

Transplant Focus Tacrolimus Inhalation Powder targets prevention of lung transplant rejection, creating a potential addressable market in transplant centers and hospital networks that manage immunosuppression. Engage transplant programs, hospital formulary committees, and procurement teams to evaluate inhaled tacrolimus as an alternative or adjunct to systemic therapy, emphasizing local delivery and reduced systemic exposure. Build pilot collaborations with major transplant centers.

Inhaled Antifungals Voriconazole Inhalation Powder positions TFF in the inhaled antifungal space; potential customers include pulmonology, infectious disease, and transplant departments. Use hospital formulary teams and infectious disease pharmacoeconomics to assess cost-benefit, infection prevention, and patient outcomes for invasive fungal infection prophylaxis in high risk populations.

Platform Licensing The TFF platform enables turning more molecules into inhalable therapies and is protected by multiple patents. Explore licensing or co development arrangements with pharma companies seeking to accelerate inhalation programs across respiratory, antiviral, or vaccine adjuvant spaces. Build a partner value proposition around faster path to clinic, IP protection, and scalable manufacturing.

Growth Funding Recent fundraising and mid range revenue indicate growth potential; prospect for strategic investments, milestone driven collaborations, or joint ventures that align with near term clinical milestones. Tailor outreach to investors and potential pharma partners seeking early stage inhalation technology assets.